Hydrocortisone (Hydrocortisone) Patent Expiration, LOE Window & CMS Spending

Hydrocortisone (Hydrocortisone) by Panray Sub Ormont Drug And Chemical: Off-Patent Genericized (AB Competition), 6 AB generics, $79.8M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPanray Sub Ormont Drug And Chemical
FDA Application & PathwayN009659 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors6
2024 CMS Total Public Spend$79.8M
2024 Medicare Part D Spend$45.5M
2024 Medicaid Spend$34.3M
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 25.8% 2-yr change)